Literature DB >> 15256446

Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.

Hongzhen Li1, Tommi J Ahonen, Kalle Alanen, Jianwu Xie, Matthew J LeBaron, Thomas G Pretlow, Erica L Ealley, Ying Zhang, Martti Nurmi, Baljit Singh, Paula M Martikainen, Marja T Nevalainen.   

Abstract

We have recently identified signal transducer and activator of transcription 5 (Stat5) as a critical survival factor for prostate cancer cells. We now report that activation of Stat5 is associated with high histological grade of human prostate cancer. Specifically, immunohistochemical analysis demonstrated a strong positive correlation with activation of Stat5 and high Gleason score in 114 human prostate cancers. To investigate the mechanisms underlying constitutive activation of Stat5 in prostate cancer, a dominant-negative mutant of Janus kinase 2 (Jak2) was delivered by adenovirus to CWR22Rv cells. Dominant-negative-Jak2 effectively blocked the activation of Stat5 whereas wild-type Jak2 enhanced activation, indicating that Jak2 is the main kinase that phosphorylates Stat5 in human prostate cancer cells. A ligand-induced mechanism for activation of Stat5 in prostate cancer was suggested by the ability of prolactin (Prl) to stimulate activation of both Jak2 and Stat5 in CWR22Rv human prostate cancer cells and in CWR22Rv xenograft tumors. In addition, Prl restored constitutive activation of Stat5 in five of six human prostate cancer specimens in ex vivo long-term organ cultures. Finally, Prl protein was locally expressed in the epithelium of 54% of 80 human prostate cancer specimens with positive correlation with high Gleason scores and activation of Stat5. In conclusion, our data indicate that increased activation of Stat5 was associated with more biologically aggressive behavior of prostate cancer. The results further suggest that Jak2 is the principal Stat5 tyrosine kinase in human prostate cancer, possibly activated by autocrine/paracrine Prl.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256446     DOI: 10.1158/0008-5472.CAN-03-3499

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

Review 1.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

2.  Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma.

Authors:  Yinling Mao; Zhiwei Li; Changjie Lou; Yanqiao Zhang
Journal:  Int J Colorectal Dis       Date:  2010-11-16       Impact factor: 2.571

3.  Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Authors:  Khatri Latha; Ming Li; Vaibhav Chumbalkar; Anupama Gururaj; YeoHyeon Hwang; Sumana Dakeng; Raymond Sawaya; Kenneth Aldape; Webster K Cavenee; Oliver Bogler; Frank B Furnari
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

Review 4.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

5.  Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

Authors:  Cheryn Song; Sun-Young Jun; Jun-Hyuk Hong; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-06       Impact factor: 4.553

6.  Bromodomain and Extraterminal Inhibition by JQ1 Produces Divergent Transcriptional Regulation of Suppressors of Cytokine Signaling Genes in Adipocytes.

Authors:  Paula Mota de Sá; Allison J Richard; Jacqueline M Stephens
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

7.  Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Authors:  M Victoria Recouvreux; J Boyang Wu; Allen C Gao; Svetlana Zonis; Vera Chesnokova; Neil Bhowmick; Leland W Chung; Shlomo Melmed
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

8.  Preferential cytotoxicity of the type I ribosome inactivating protein alpha-momorcharin on human nasopharyngeal carcinoma cells under normoxia and hypoxia.

Authors:  Wen Liang Pan; Jack Ho Wong; Evandro Fei Fang; Yau Sang Chan; Tzi Bun Ng; Randy Chi Fai Cheung
Journal:  Biochem Pharmacol       Date:  2014-03-14       Impact factor: 5.858

9.  Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.

Authors:  Ayush Dagvadorj; Shyh-Han Tan; Zhiyong Liao; Luciane R Cavalli; Bassem R Haddad; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Authors:  Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-02-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.